Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin

Ertugliflozin, an inhibitor of sodium‐glucose cotransporter 2, is approved in the United States and European Union for the treatment of type 2 diabetes in adults, both as monotherapy and as part of fixed‐dose combination (FDC) therapies with either sitagliptin or immediate‐release metformin. The eff...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacol Drug Dev
Autors principals: Sahasrabudhe, Vaishali, Fediuk, Daryl J., Matschke, Kyle, Shi, Haihong, Liang, Yali, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas K.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6618047/
https://ncbi.nlm.nih.gov/pubmed/30427588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.629
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars